Johnson & Johnson: Pain trials

The registry lists 10 Pain studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 3 have results posted.

Phase 2 2Phase 3 6Phase 4 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN)TerminatedNCT01063868Phase 3Results posted
• Tapentadol (CG5503)CompletedNCT00421928Phase 3Results posted
• A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For SafetyTerminatedNCT00364533Phase 3Results posted
• A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following BunionectomyCompletedNCT05868122Phase 3
• A Study of an Acetaminophen/Naproxen Sodium Fixed Combination, Acetaminophen and Naproxen Sodium in Postoperative Dental PainCompletedNCT05761574Phase 3
• A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related PainCompletedNCT00929188Phase 2
• An Efficacy and Safety Study of Low-dose Transdermal Therapeutic System (TTS)-Fentanyl D-Trans in Taiwan Participants With Cancer PainCompletedNCT00771199Phase 4
• An Efficacy and Safety Study of Tramadol/Acetaminophen Versus Diclofenac in the Treatment of Pain in Participants With Ankylosing Spondylitis Receiving Stable Treatment of Disease Modifying Anti-rheumatic Drugs (DMARDs)TerminatedNCT00766402Phase 4
• A Study on Efficacy (Effectiveness), Safety, and Impact on Quality of Life Measures of Dilaudid CR (Controlled Release);, Hydromorphone HCl in Patients With Chronic Low Back PainCompletedNCT00398788Phase 2
• A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic PainCompletedNCT00364546Phase 3